Compounded GLP-1 Medications

If you’ve spent any time researching GLP-1 medications, you’ve almost certainly come across ads for cheaper versions — often from online telehealth companies or compounding pharmacies. “Semaglutide for $200/month!” “Tirzepatide without insurance!” The prices are dramatically lower than brand-name Ozempic, Wegovy, or Zepbound. And for a lot of people who can’t get insurance coverage, those prices represent the only realistic path to treatment.

This is one of the most complicated topics in the GLP-1 space right now. It sits at the intersection of federal drug regulation, pharmacy law, patient access, drug safety, and a rapidly evolving legal battle between major pharmaceutical companies, compounding pharmacies, the FDA, and the courts. There’s no simple “good guys and bad guys” story here — there are legitimate concerns on every side.

This page gives you a clear picture of what compounded GLP-1s actually are, how they differ from the brand-name versions, and what the real risks look like — so you can make an informed decision rather than one based on marketing or fear.

---

What “Compounded” Actually Means

A compounded medication is one that a pharmacy mixes or prepares itself, rather than dispensing a pre-made product from a manufacturer. Compounding has been a legitimate part of pharmacy practice for decades — it exists to fill gaps that mass-produced medications can’t cover. A patient who’s allergic to a dye in a commercial tablet, for example, might get a compounded version made without that ingredient.

Traditionally, compounding was small-scale and patient-specific: your doctor writes a prescription, a pharmacist mixes it for you. It was never intended to be mass production — that’s what FDA-approved manufacturing is for.

With GLP-1 medications, compounding has scaled far beyond that traditional model. Pharmacies have been producing thousands of doses of semaglutide and tirzepatide, selling them through telehealth platforms and online marketplaces at prices well below the brand-name versions. That’s where things get complicated — and where the FDA has stepped in.

---

The Two Types of Compounding Pharmacies

Federal law creates two categories of compounding pharmacies under the Drug Quality and Security Act (2013), and the rules are very different for each.[1]

503A Pharmacies — Traditional Compounding

These are your traditional compounding pharmacies — often local, independent pharmacies. The key features:

• Patient-specific. Every batch is made for a named patient with a valid prescription.
• Small-scale. They’re not producing large inventories.
• State-regulated. Overseen by state boards of pharmacy, not directly by the FDA.
• No FDA registration required. They operate under state pharmacy law.

A 503A pharmacy can compound a GLP-1 medication for you if your doctor writes a prescription specifically for you. They cannot mass-produce it for general distribution.

503B Pharmacies — Outsourcing Facilities

These are larger operations that are federally registered with the FDA. The key differences:

• Can produce without individual prescriptions. They compound in larger batches for distribution to healthcare facilities.
• FDA-registered and inspected. Must follow current Good Manufacturing Practices (cGMP).
• Can distribute to hospitals, clinics, and doctor’s offices. Not just individual patients.
• Subject to FDA oversight. Including inspections, adverse event reporting, and enforcement actions.

The 503B model is where much of the large-scale compounded GLP-1 production has happened — and where much of the current legal battle is focused.

---

The Shortage: How This Got So Big

Compounding pharmacies can legally produce copies of FDA-approved medications in one specific situation: when the brand-name drug is on the FDA’s official drug shortage list. That’s the legal gateway — and for GLP-1 medications, it was wide open for years.

The Timeline

2022-2024: Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were both listed on the FDA’s drug shortage list. Demand was overwhelming supply. Patients couldn’t find the medications at pharmacies even with valid prescriptions. This shortage created the legal basis for compounding pharmacies to step in — and step in they did, aggressively.

October 2024: The FDA declared the tirzepatide shortage “resolved” and removed it from the shortage list. This triggered the wind-down of legal compounding for tirzepatide, with the FDA providing a transition period for patients already receiving compounded versions. Compounding pharmacies and their trade groups challenged this decision in court.[2]

December 2024: After briefly reconsidering, the FDA issued a Declaratory Order re-confirming that the tirzepatide shortage was resolved. The legal battle intensified — the Outsourcing Facilities Association filed lawsuits, but in May 2025 a federal court backed the FDA’s decision.[2]

February 2025: The FDA declared the semaglutide shortage resolved as well, removing it from the shortage list. This effectively closed the legal door for compounding both major GLP-1 medications.[3]

What “Shortage Resolved” Means for Compounding

Once a drug comes off the shortage list, compounding pharmacies lose their legal basis for producing copies. The FDA has provided transition periods — typically 60-90 days — for patients to switch to brand-name products. After that, continued compounding is technically unauthorized.

In practice, enforcement has been uneven. Some compounding pharmacies have continued producing GLP-1 medications through various legal arguments. Others have stopped. The situation remains fluid and varies by state.

---

The Salt Form Issue: Not Exactly the Same Molecule

This is a critical detail that most advertising glosses over.

Brand-name Ozempic and Wegovy use semaglutide — the specific molecule that went through years of clinical trials involving tens of thousands of patients. Many compounding pharmacies use semaglutide sodium or semaglutide acetate — salt forms of the molecule that are chemically different from what’s in the approved products.

The FDA has been explicit about this: salt forms like semaglutide sodium and semaglutide acetate are different active ingredients than the semaglutide used in approved products. The FDA does not have data confirming that these salt forms have the same chemical and pharmacologic properties. No clinical trials have been conducted on these alternative forms to establish their safety, effectiveness, or proper dosing.[4]

What does this mean in practical terms? It means that when a compounding pharmacy says they’re giving you “semaglutide,” they may be giving you a chemically related but distinct compound that hasn’t been studied the way the original was. The dose that works for brand-name semaglutide may not translate directly to the salt form. The side effect profile may differ. The absorption rate may differ.

This isn’t the same as a generic medication, where the FDA requires proof that the generic is bioequivalent to the brand name. Compounded medications don’t go through that process.

---

Safety: The Real Concerns

The safety question isn’t theoretical. As of mid-2025, real harm has been documented.[5]

Reported Problems

• Over 600 adverse event reports tied to compounded semaglutide have been filed with the FDA.
• Over 100 hospitalizations linked to compounded GLP-1 products, according to Novo Nordisk’s reports to the FDA.
• At least 10 deaths associated with compounded semaglutide.
• Dosing errors — the FDA has flagged cases where compounded products contained incorrect concentrations, leading to patients receiving far more or far less medication than intended.
• Sterility failures — injectable medications must be sterile. Multiple compounding pharmacies have been cited for contamination issues and inadequate sterility testing.

FDA Enforcement Actions

The FDA has significantly escalated enforcement:

• More than 50 warning letters sent to GLP-1 compounders and manufacturers in 2025, citing violations ranging from contamination to misleading advertising.[6]
• Inspections of 503B outsourcing facilities have uncovered manufacturing deficiencies, inadequate quality controls, and failure to report adverse events.
• The SAFE Drugs Act of 2025 was introduced in Congress to expand FDA oversight of compounded GLP-1 drugs and the telehealth providers that prescribe them.

Why Injectables Are Higher Risk for Compounding

This is worth understanding: not all compounded medications carry the same risk. Compounding an oral capsule is relatively straightforward. Compounding a sterile injectable — which is what semaglutide and tirzepatide are — is a fundamentally different and more dangerous operation.

Injectable medications must be:

• Sterile — free of bacteria, fungi, and other contaminants
• Precisely dosed — the concentration must be exact
• Properly stored — maintaining the cold chain for peptide stability
• Free of particulates — no visible or sub-visible particles

Getting any of these wrong with an injectable can cause serious harm — infections, overdoses, or medication that simply doesn’t work because the peptide has degraded.

---

Cost: The Core of the Issue

The reason compounded GLP-1s exist at the scale they do isn’t complicated: people can’t afford the brand-name versions, and their insurance won’t cover them.

The access gap is real. As of 2025, many private insurers still don’t cover GLP-1 medications for weight management (as opposed to diabetes). Medicare only began covering certain GLP-1s for obesity in 2025, with broader coverage expected in 2026. For the millions of people who want treatment but don’t have coverage, compounded versions have been the only financially realistic option.[7]

This creates a genuine ethical tension: the brand-name versions are safer and better studied, but they’re also inaccessible for many people. The compounded versions are accessible but carry real risks. There’s no clean answer.

---

The Legal Battle

The compounded GLP-1 market has spawned multiple overlapping legal fights.[2][6]

FDA vs. Compounding Pharmacies: The FDA has moved to restrict compounding now that the shortages are officially resolved. Compounding pharmacy trade groups have challenged these decisions in court, arguing that the shortages aren’t truly resolved for all patients and dose strengths.

Novo Nordisk and Eli Lilly vs. Compounders: Both pharmaceutical companies have filed lawsuits against compounding pharmacies, alleging trademark infringement, patent violations, and the sale of what they call “counterfeit” products. Some compounders have filed counter-suits alleging antitrust violations — claiming the drug companies are coordinating to crush affordable competition.

State-Level Variation: Some states have passed or proposed laws that affect compounding access differently. The regulatory landscape varies significantly depending on where you live.

The Bottom Line on Legal Status (Early 2026): With both semaglutide and tirzepatide off the federal shortage list, the legal basis for large-scale compounding has narrowed significantly. Some compounding continues under various legal theories and during enforcement transition periods, but the trend is toward restriction. This is an evolving situation — what’s true today may change in the coming months.

---

What Medical Organizations Say

Major medical organizations have generally aligned with the FDA’s concerns about compounded GLP-1 medications:

• The Endocrine Society and the Journal of the Endocrine Society published a 2025 editorial titled “Global Rise of Compounded Weight-Loss Medicines: A Worrisome Trend,” highlighting concerns about quality control, dosing accuracy, and lack of clinical trial data for compounded products.[8]
• The Obesity Medicine Association has emphasized that FDA-approved medications should be the first-line option whenever accessible.
• The American Medical Association has focused on the broader access problem — advocating for insurance coverage expansion as the solution, rather than accepting compounded alternatives as the answer.

The medical consensus isn’t “compounding is evil” — it’s “compounding exists because access is broken, and fixing access would be better than accepting the risks of an unregulated parallel market.”

---

If You’re Considering Compounded GLP-1s

This isn’t a recommendation for or against — it’s a list of things to know and questions to ask.

Questions for the Provider or Pharmacy

1. Is this a 503A or 503B pharmacy? 503B facilities have FDA registration and oversight. 503A pharmacies are regulated only at the state level.
2. What form of semaglutide (or tirzepatide) do they use? If they're using a salt form (semaglutide sodium, semaglutide acetate), understand that this is not the same active ingredient as the brand-name product.
3. Can they provide certificates of analysis? These documents show that a third-party lab has verified the potency and sterility of the product. Reputable pharmacies will have these.
4. Do they have a recent FDA inspection report (for 503B)? Inspection results are public. Ask about the outcome.
5. What happens if there's a problem? What adverse event reporting procedures do they follow?

Red Flags

---

The Bigger Picture

The compounded GLP-1 market didn’t appear because people wanted to take shortcuts. It appeared because the healthcare system created a gap: FDA-approved medications that work remarkably well, but that millions of people can’t access because of cost and insurance limitations.

The solution to that gap isn’t more compounding — it’s better access to the approved products. That means broader insurance coverage (which is slowly expanding), manufacturer pricing changes (like Lilly’s direct-to-consumer pricing through LillyDirect), and competition from generic and biosimilar versions when patents eventually expire.

In the meantime, the compounded market exists in a space between “necessary bridge for patients who have no other option” and “largely unregulated parallel drug supply with real safety risks.” Where a particular pharmacy falls on that spectrum depends on their practices, oversight, and integrity — and that’s exactly why asking the right questions matters.

---